oral cancer and oral precancerous lesions in inflammatory bowel diseases: A systematic review

Journal of Crohn's and Colitis

Volumn 9, Issue 11, 2015, Pages 1043-1052

  Katsanos, Konstantinos H ^a   Roda, Giulia ^a   Brygo, Alexandre ^b   Delaporte, Emmanuel ^b   Colombel, Jean Frédéric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIV LILLE   (France)

Author keywords

anti TNF ; azathioprine; biological therapies; Crohn's disease; immunosuppressant; Inflammatory bowel disease; oral cancer; oral malignancy; oral precancerous lesions; ulcerative colitis

Indexed keywords

BIOLOGICAL PRODUCT; CALCINEURIN INHIBITOR; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE;

BIOLOGICAL THERAPY; BUCCAL CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CORTICOSTEROID THERAPY; EPSTEIN BARR VIRUS; ERYTHROLEUKOPLAKIA; ERYTHROPLASIA; GINGIVAL CANCER; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LEUKOPLAKIA; LICHEN PLANUS; LIP CANCER; MOUTH CANCER; MOUTH DISEASE; PRECANCER; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TONGUE CANCER; WART VIRUS; COMPLICATION; HEALTH; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MOUTH NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS;

GLOBAL HEALTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 84963777949     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv122     Document Type: Review

References (72)

1. Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology 2003;185:229-40
2. Campisi G, Giovannelli L. Controversies surrounding human papilloma virus infection, head and neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol 2009;1:8
3. Hirshberg A, Buchner A. Metastatic tumours to the oral region. An overview. Eur J Cancer B Oral Oncol 1995;31:355-60
4. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papilloma virus infections and related diseases. Vaccine 2013;31:F1-31
5. Huang SH, O'Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal 2013;18:e233-4
6. Barton JR, Riad MA, Gaze MN, Maran AG, Ferguson A. Mucosal immunodeficiency in smokers, and in patients with epithelial head and neck tumours. Gut 1990;31:378-82
7. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:39-44
8. Laheij AM, de Soet JJ, von dem Borne PA, et al. Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer 2012;20:3231-40
9. King GN, Healy CM, Glover MT, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995;332:1052-7
10. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for post transplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002;8:482-7
11. Di Stasio D, Guida A, Salerno C, et al. Oral lichen planus: a narrative review. Front Biosci 2014;6:370-6
12. Dunsche A, Härle F. [Precancer stages of the oral mucosa: a review.] Laryngorhinootologie 2000;79:423-7
13. Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK. Proliferative verrucous leukoplakia [PVL]: a review of an elusive pathologic entity! Adv Anat Pathol 2013;20:416-23
14. Rushing EC, Hoschar AP, McDonnell JK, Billings SD. Iatrogenic oral hairy leukoplakia: report of two cases. J Cutan Pathol 2011;38:275-9
15. Itin P. Oral hairy leukoplakia in HIV-negative immunosuppressed patients. J Am Acad Dermatol 1990;23:957-8
16. Wilczynska-Borawska M, Malyszko J, Stokowska W. [Oral cavity changes in patients after kidney transplantation and preventive-treatment algorithms.] Przegl Lek 2010;67:1322-4
17. Piselli P, Verdirosi D, Cimaglia C, et al. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors. Best Pract Res Clin Obstet Gynaecol 2014;28:1251-65
18. Rinaldi M, Pellegrini C, D'Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001;19:696-701
19. De la Rosa-Garcia E, Mondragon-Padilla A. Oral lesions associated to immunosuppression in kidney transplant patients. Rev Med Inst Mex Seguro Soc 2014;52:442-7
20. Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014;43:489-97
21. Aydin F, Yuksel EP, Senturk N, Canturk T, Turanli AY. Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination. Cutan Ocul Toxicol 2014;33:181-3
22. Kanee B. Oral florid papillomatosis complicated by verrucous squamous carcinoma. Treatment with methotrexate. Arch Dermatol 1969;99:196-202
23. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001;85:683-6
24. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71
25. Pereira DF, Pinheiro MM, Silva PF, Teodoro GR, Brighenti FL, Koga-Ito CY. Influence of TNF-a blockers on the oral prevalence of opportunistic microorganisms in ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:679-85
26. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011;17:758-66
27. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9
28. Pagano JS. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians 1999;111:573-80
29. Birek C, Patterson B, Maximiw WC, Minden MD. EBV and HSV infections in a patient who had undergone bone marrow transplantation: oral manifestations and diagnosis by in situ nucleic acid hybridization. Oral Surg Oral Med Oral Pathol 1989;68:612-7
30. Schmidt-Westhausen A, Gelderblom HR, Hetzer R, Reichart PA. Demonstration of Epstein-Barr virus in scrape material of lateral border of tongue in heart transplant patients by negative staining electron microscopy. J Oral Pathol Med 1991;20:215-7
31. Zitelli KB, Zedek D, Ranganathan P, Amerson EH. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-a inhibitors and cutaneous carcinoma risk. Cutis 2013;92:35-9
32. López-Pintor RM, Hernández G, de Arriba L, de Andrés A. Lip cancer in renal transplant patients. Oral Oncol 2011;47:68-71
33. Nishihara K, Nozoe E, Hirayama Y, Miyawaki A, Semba I, Nakamura N. A case of small cell carcinoma in the buccal region. Int J Oral Maxillofac Surg 2009;38:1000-3
34. Hasegawa W, Pond GR, Rifkind JT, et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005;35:51-5
35. Altintas A, Vardar MA, Aridogan N, Doran F, Tuncer I. Choriocarcinoma metastatic to the maxillary gingiva. Eur J Surg Oncol 1995;21:579-80
36. Maraki D, Hengge UR, Becker J, Boecking A. Very early cytological and DNA-cytometric diagnosis of in situ carcinoma in an immunosuppressed liver transplant recipient. J Oral Pathol Med 2006;35:58-60
37. Byun JH, Park BW, Kim JR, Lee GW, Lee JH. Squamous cell carcinoma of the tongue after bone marrow transplant and graft-versus-host disease: a case report and review of the literature. J Oral Maxillofac Surg 2008;66:144-7
38. Vargas SO, Perez-Atayde AR, Padwa BL, Springer KM. Immunosuppression-related fibroproliferative polyps of the tongue. Pediatr Dev Pathol 2007;10:256-65
39. Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:525-41
40. Végso G, Járay J. [Malignant tumors following renal transplantation.] Orv Hetil 2007;148:2115-23
41. Cai C, Chernock RD, Pittman ME, El-Mofty SK, Thorstad WL, Lewis JS Jr. Keratinizing-type squamous cell carcinoma of the oropharynx: p16 overexpression is associated with positive high-risk HPV status and improved survival. Am J Surg Pathol 2014;38:809-15
42. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol 2014;109:212-23
43. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5
44. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1308-19
45. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3
46. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
47. Katsanos KH, Tatsioni A, Pedersen N, et al. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study. J Crohns Colitis 2011;5:430-42
48. Katsanos K, Ferrante M, Fidder H, et al. Long-term safety of azathioprine treatment in inflammatory bowel disease: results from a single referral center. J Crohns Colitis 2007;1:2
49. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32
50. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-a antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406-13
51. Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutis 2009;84:325-8
52. Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol 2012;37:879-81
53. Moss AC, Treister NS, Marsee DK, Cheifetz AS. Clinical challenges and images in GI. Oral lichenoid reaction in a patient withCrohn's disease receiving infliximab. Gastroenterology 2007;132:488
54. Mocciaro F, Orlando A, Renna S, Rizzuto MR, Cottone M. Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease. J Crohns Colitis 2011;5:173-4
55. Flückiger R, Laifer G, Itin P, Meyer B, Lang C. Oral hairy leukoplakia in a patient with ulcerative colitis. Gastroenterology 1994;106:506-8
56. Ben Slama L. Precancerous lesions of the buccal mucosa. Rev Stomatol Chir Maxillofac 2001;102:77-108
57. Beaugerie L, Sokol H, Seksik P. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis 2009;27:375-81
58. Pedersen EG, Pottegård A, Hallas J, et al. Use of azathioprine for nonthymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013;20:942-8
59. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105:1604-9
60. Li AC, Warnakulasuriya S, Thompson RP. Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine: case report. Eur J Gastroenterol Hepatol 2003;15:185-7
61. Vilas-Boas F, Magro F, Balhau R, et al. Oral squamous cell carcinoma in a Crohn's disease patient taking azathioprine: case report and review of the literature. J Crohns Colitis 2012;6:792-5
62. Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296-305
63. Beaugerie L, Carrat F, Colombel JF, et al. CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-23
64. Rousseau A, Taberne R, Siberchicot F, Fricain JC, Zwetyenga N. Cancer of the cheek in a patient under etanercept. Rev Stomatol Chir Maxillofac 2009;110:306-8
65. Antoniou C, Dessinioti C, Vergou T, et al. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with highneed psoriasis. J Eur Acad Dermatol Venereol 2010;24:1413-20
66. Rouxel AM, Le Toux G, Misery L. Tacrolimus mouthwash as second-line treatment for erosive oral lichen planus. Ann Dermatol Venereol 2010;137:648-9
67. Kuijken I, Bavinck JN. Skin cancer risk associated with immunosuppressive therapy in organ transplant recipients: epidemiology and proposed mechanisms. BioDrugs 2000;14:319-29
68. Torres J, Buche S, Delaporte E, Colombel JF. Skin side effects of inflammatory bowel disease therapy. Inflamm Bowel Dis 2013;19:1086-98
69. Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013;62:1523-8
70. Beaugerie L. Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis 2013;31:254-9
71. De la Rosa-García E, Mondragón-Padilla A, Irigoyen-Camacho ME, Bustamante-Ramírez MA. Oral lesions in a group of kidney transplant patients. Med Oral Patol Oral Cir Bucal 2005;10:196-204
72. Komitowski DD, Helfrich SI, Schmitt BA, Freese KU. Subclinical human immunodeficiency virus-related changes in oral mucosa shown by image analysis of tongue smears. Am J Clin Pathol 1993;100:433-8